Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

20°
- Newport, VT (05855)
  Today
  
  Overcast. A few flurries or snow showers possible. High 21F. Winds WNW at 10 to 20 mph..
  
  Tonight
  
  Partly cloudy. Very cold. Low near -5F. Winds W at 10 to 20 mph.
  
  Updated: December 4, 2025 @ 1:05 pm
- Full Forecast

Site search

Home
News
Sports
Entertainment
- Calendar
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
- Place an ad
Archives
Best of 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

919.03 -2.76 (-0.30%)

Streaming Delayed Price Updated: 2:12 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say ↗

September 29, 2022

Via Benzinga

Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection ↗

September 21, 2022

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 11, 2022

Via Benzinga

Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate ↗

August 11, 2022

The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult...

Via Benzinga

Argenx's Drug Scores European Approval For Muscular Fatigue Disorder ↗

August 11, 2022

Via Benzinga

Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike ↗

July 29, 2022

Via Benzinga

argenx: Q2 Earnings Insights ↗

July 28, 2022

argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: argenx Q2 Earnings ↗

July 28, 2022

argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

What 5 Analyst Ratings Have To Say About argenx ↗

July 25, 2022

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022 ↗

July 29, 2022

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022

July 28, 2022

From argenx SE

Via GlobeNewswire

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space ↗

May 24, 2022

Via Benzinga

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study ↗

May 05, 2022

Via Benzinga

argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update

July 28, 2022

From argenx SE

Via GlobeNewswire

Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know ↗

July 25, 2022

Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at...

Via Benzinga

Golden Cross Appears Before argenx Investors ↗

May 16, 2022

If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: argenx Q1 Earnings ↗

May 05, 2022

argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores ↗

April 05, 2022

Argenx SE (NASDAQ: ARGX) announced

Via Benzinga

Recap: argenx Q4 Earnings ↗

March 03, 2022

argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022 ↗

May 03, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

April 01, 2022

From argenx SE

Via Business Wire

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx ↗

March 22, 2022

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical...

Via Benzinga

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder ↗

March 22, 2022

Argenx SE (NASDAQ: ARGX) ) has

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗

March 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

March 22, 2022

From argenx SE

Via Business Wire

What 8 Analyst Ratings Have To Say About argenx ↗

March 07, 2022

argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 4...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Featured Local Savings

Sections

News
Sports
Entertainment
Obituaries
Local Events
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

Newport Daily Express

NewportVermontDailyExpress.com
178 Hill Street
Newport, VT 05855
Phone: 802-334-6568
Email: editor@newportvermontdailyexpress.com

Facebook

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Newport, VT (05855)

Today

Tonight

argenx SE - American Depositary Shares (NQ:ARGX)

All News about argenx SE - American Depositary Shares

Featured Local Savings

Sections

Services

Newport Daily Express